Mr. Riccitelli serves as Chairman of the Board. Most recently Mr. Riccitelli served as President and CEO and a director on the board of directors of Signal Genetics, a publicly traded molecular diagnostic company focused on serving the needs of patients suffering from Multiple Myeloma. Previously, Mr. Riccitelli has served as an independent consultant, as the PEVP and COO of Genoptix, a publicly traded diagnostic services company focused on the needs of community hematologists and oncologists. Mr. Riccitelli has also held a number of R&D and general management leadership positions for Becton, Dickinson and Company, including most recently as a VP and GM and as a board member for BD Ventures. Mr. Riccitelli received a B.A. in Biology from Washington and Jefferson College and a M.S. Eng. degree from The University of Texas in Mechanical & Biomedical Engineering.
David Cohen is Executive Vice President and co-owner of Standard Oil of Connecticut, Inc., the largest independently-owned energy retailing company in Connecticut. David Cohen has also founded a number of highly successful ventures, including: Standard Security Systems, one of the largest electronic security companies in Connecticut; ResCom Energy, a supplier of deregulated electricity in Connecticut, Delaware, Illinois, New Jersey, Ohio, and Pennsylvania; Foresite MSP, a provider of managed security and cyber consulting services; and My Gene Counsel, a cancer bioinformatics company. Mr. Cohen serves on the boards of the following companies: eBrevia, Emme Controls, My Gene Counsel, Sirona Medical Technologies, and The Platt & LaBonia Company. Mr. Cohen holds a BA degree from Harvard College, Class of 1980, and an MBA degree from the Harvard Business School, Class of 1984.
Ilan Danieli has served as Precipio's CEO since founding the company in early 2011. With over 20 years managing small and medium-size companies, some of his previous experiences include COO of Osiris, a publicly-traded company based in New York City with operations in the US, Canada, Europe and Capital Management, a multi-billion dollar hedge fund; and in various other entrepreneurial ventures. Ilan holds an MBA from the Darden School at the University of Virginia, and a BA in Economics from Bar-Ilan University in Israel.
Dr. Cossman was a founder of and served as Chief Executive Officer and Chairman of the Board at, United States Diagnostic Standards, Inc. from 2009 to 2014 and served as a member of the board of directors of The Personalized Medicine Coalition from 2008 to 2014. Prior to that, he served as Chief Scientific Officer and a member of the board of directors of The Critical Path Institute and as Medical Director of Gene Logic, Inc.; he was Professor and Chairman of the Department of Pathology at Georgetown University Medical Center and held the Oscar Benwood Hunter Chair of Pathology at Georgetown; he served as Senior Investigator in Hematopathology at the National Cancer Institute. He is currently a medical advisor to Epigenomics AG. Dr. Cossman holds a B.S. from the University of Michigan and an M.D. from the University of Michigan Medical School. He is board-certified in pathology and trained in pathology and hematopathology at the University of Michigan, Stanford University and the National Institutes of Health.
President and Chief Executive Officer of Bantam Pharmaceutical, LLC, since March 2016. Former Senior Vice President and General Manager, Discovery and Development Services, at Albany Molecular Research, Inc. and Corporate Vice President of Global Discovery Research Services at Charles River Laboratories. Former President and a member of the Board of Directors of the David H. Murdock Research Institute, former Vice President and Site Head at Merck Frosst and various positions at GlaxoSmithKline. Bachelor of Science degree in Biology and Chemistry from North Carolina State University, a Master in Business Administration from Duke University, Fuqua School of Business, and a Ph.D. in Biophysical Chemistry from Saint Louis University School of Medicine.
Mark Rimer is a partner at Kuzari Group, a boutique private investment group with a broad mandate to invest in full or partial buy-outs, growth capital and venture capital across a broad range of industries. Mark serves on the Board of several companies, including Precipio, and is actively engaged with numerous portfolio companies. Prior to joining Kuzari, Mark worked for a London-based private equity group - RP Capital Group, managing a number of investments in emerging markets. Mark is a Chartered Accountant, earned his undergraduate degree in Politics and Economics from Bristol University, and his MBA from the NY Stern School of Business.
Doug joined InterWest's healthcare team in 2009, focusing on biopharmaceutical, diagnostic and medical device investments, and portfolio company support. Prior to joining InterWest, Doug was a vice president at New Leaf Venture Partners where he spent three years focusing on biopharmaceutical, medical device, and diagnostics investments. Prior to joining New Leaf, Doug was a project leader with The Boston Consulting Group where he was a member of the Health Care Practice Area, consulting for leading pharmaceutical and biotech companies. Previously, he worked for Centocor (a J&J operating company) in the Global Biologic Strategic Marketing Group. Doug received an A.B. in economics with honors and distinction, and a B.S. in biology with distinction, from Stanford. He has an M.D. from the University of Pennsylvania School of Medicine and an M.B.A. from Wharton.